Literature DB >> 33425757

The Suppressing Effects of Dkk3 Expression on Aggressiveness and Tumorigenesis of Colorectal Cancer.

Shuang Zhao1, Chang-Lai Hao2, En-Hong Zhao3, Hua-Mao Jiang4, Hua-Chuan Zheng1.   

Abstract

Dkk3 has been discovered during comparison of immortalized and parental cells. Its expression has been shown to reduce colony formation and induce apoptosis of cancer cells, acting as a tumor suppressor. Herein, we demonstrate that Dkk3 overexpression or protein treatment may inhibit colorectal cancer cell proliferation, migration, and invasion and that they may promote apoptosis and G2 phase arrest with hypoexpression of Bcl-2, cdc25B, cdc25c, N-cadherin, slug, and twist and hyperexpression of Bax and E-cadherin. This effect is consistent with that of recombinant Dkk3 exposure and blocked with anti-Dkk3 antibody. Dkk3 deletion in intestinal cells was not associated with the emergence of epithelial lesions; however, adenoma emerged after sodium desoxycholate treatment. At both mRNA and protein levels, Dkk3 expression was higher in normal than in cancer tissues (p<0.05). Dkk3 mRNA expression was negatively associated with its promoter methylation, growth pattern, differentiation, and favorable prognosis in the patients with colorectal cancer (p<0.05). Dkk3-related signal pathways in colorectal cancer included those of cellular adhesion and migration, melanogenesis, chemokine, Hedgehog, JAK-STAT, TOLL-like receptor, TGF-β, MAPK, and calcium signaling (p<0.05). These findings indicate that Dkk3 expression levels can help assess cancer aggressiveness and patient prognosis. It might also suppress aggressive phenotypes and tumorigenesis as a molecular target in gene therapy.
Copyright © 2020 Zhao, Hao, Zhao, Jiang and Zheng.

Entities:  

Keywords:  Dkk3; aggressive phenotypes; colorectal cancer; pathological behaviors; prognosis; tumorigenesis

Year:  2020        PMID: 33425757      PMCID: PMC7794014          DOI: 10.3389/fonc.2020.600322

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  4 in total

1.  Identification and Validation of a Six Immune-Related Genes Signature for Predicting Prognosis in Patients With Stage II Colorectal Cancer.

Authors:  Xianzhe Li; Minghao Xie; Shi Yin; Zhizhong Xiong; Chaobin Mao; Fengxiang Zhang; Huaxian Chen; Longyang Jin; Ping Lan; Lei Lian
Journal:  Front Genet       Date:  2021-05-04       Impact factor: 4.599

2.  MiR-363-3p promotes prostate cancer tumor progression by targeting Dickkopf 3.

Authors:  Li-Zhe Xu; Jin-Zhuo Ning; Yuan Ruan; Fan Cheng
Journal:  J Clin Lab Anal       Date:  2022-03-18       Impact factor: 2.352

3.  Apogossypolone Inhibits Cell Proliferation and Epithelial-Mesenchymal Transition in Cervical Cancer via Activating DKK3.

Authors:  Yuling Li; Jinfeng Qu; Lu Liu; Yu Sun; Junhua Zhang; Sai Han; Youzhong Zhang
Journal:  Front Oncol       Date:  2022-07-18       Impact factor: 5.738

4.  Crosstalk Between DNA Methylation and Gene Mutations in Colorectal Cancer.

Authors:  Maria Dobre; Alessandro Salvi; Iulia Andreea Pelisenco; Florina Vasilescu; Giuseppina De Petro; Vlad Herlea; Elena Milanesi
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.